 3. Currently receives or has received during the 60 days or 5 half-lives of the specific drug, whichever is longer before first admission to the clinical research center until the last discharge a nucleostide-analogue therapy or other anti HBV treatment interferons, experimental anti HBV drugs or vaccines 